Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 ...

Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

Q4 2024 Earnings Call Transcript April 30, 2025 PureTech Health plc beats earnings expectations. Reported EPS is $3.98, expectations were $-2.83. Operator: Greetings and welcome to the PureTech Health ...

For most of us, taking Alexandria private is a theoretical exercise. Instead, we must be content with purchasing fractions of ...

In today’s unpredictable global trade environment, with rising tariffs and tensions, investors are looking for stability.

A short squeeze is a large, short-term spike in a stock's share price that occurs when a significant number of short sellers ...

Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results ...

Biotechnology may be the stuff that dreams are made of, but more recently, the sector has been a nightmare for investors.

Siren Biotechnology is trying to raise $5 million via the type of crowdfunding round that’s rarely used by young drugmakers.

Radiopharma biotech Cellectar Biosciences is seeking strategic alternatives, opening the door to further opportunities after ...

Shipments in Canada under the SAP were resumed in Q2 and, having secured the requisite Health Canada export permits, we began ...

Novartis is buying Regulus for $800 million, picking up the biotech's experimental kidney drug that's based off a ...